Cytotherapy

Journal Title：Cytotherapy

The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.

该期刊为读者带来快速发展的人类细胞治疗领域的最新进展。这包括癌症、免疫疾病、遗传疾病、组织修复和再生医学的细胞治疗。该期刊涵盖各种细胞类型的科学、转化发展和治疗，包括造血干细胞、免疫细胞（树突状细胞、NK 细胞、T 细胞、抗原呈递细胞）、间充质基质细胞、脂肪细胞、神经、肌肉、血管和内皮细胞以及诱导性多能干细胞。我们也欢迎有关亚细胞衍生物（如外泌体）的手稿。特别关注将细胞疗法带入临床的转化研究。Cytotherapy 发表原创论文、评论、立场文件社论、评论和致编辑的信。我们欢迎“细胞治疗协议”，为读者提供用于临床生产特定细胞类型的标准操作程序。

Cytotherapy创刊于1999年，由Elsevier Inc.出版商出版，收稿方向涵盖医学 - 生物工程与应用微生物全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度 偏慢,4-8周 ，影响因子指数3.7，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。